Travere Therapeutics (TVTX) Asset Writedowns and Impairment (2015 - 2022)

Travere Therapeutics (TVTX) has 8 years of Asset Writedowns and Impairment data on file, last reported at -$1.0 million in Q4 2022.

• Quarterly Asset Writedowns and Impairment fell 17.96% year-over-year to -$1.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.0 million (up 108.63% YoY) and the FY2025 annual result came in at $684000.0, down 75.74% from the prior year.
• Asset Writedowns and Impairment eased to -$1.0 million in Q4 2022, from $329000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $25.5 million in Q1 2019 to a low of -$1.0 million in Q4 2022.
• A 4-year average of $2.9 million and a median of $481000.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment slumped 139.28% — and 2022, when it jumped 94.87%.
• Tracing TVTX's Asset Writedowns and Impairment over 4 years: stood at $25.5 million in 2019, then sank by 91.27% to $2.2 million in 2020, then tumbled by 139.28% to -$874000.0 in 2021, then fell by 17.96% to -$1.0 million in 2022.
• The last three Asset Writedowns and Impairment figures came in at -$1.0 million (Q4 2022), $329000.0 (Q3 2022), and $792000.0 (Q2 2022), per Business Quant data.